Catalyst overview
Research summary
This catalyst tracks a Phase 1/2 update for FG-3246+ enzalutamide in Cancer, Castration-resistant prostate cancer. The expected timing is based on the latest available company guidance and may change.
4/2/24 Conducted at UCSF. 5/24/24 Positive Ph1b interim results at ASCO 2024 on June 2, 2024. Ph2 study in H2 '24. 3/17/25- Topline data from the Ph2 portion in H2 2025. 11/10/25:- Topline results from the investigator-sponsored Phase 1b/2 combination study are now expected to be presented at a medical conference in Q1 2026. 02/23/26:- Ph1b/2 FG-3246+enzalutamide showed 10.1-month rPFS after one prior ARPI; data at ASCO GU.
Verification
Confirm timing and program details against the company announcement or filing.